Designer probiotics could reduce obesity

December 22, 2010

Specially designed probiotics can modulate the physiology of host fat cells say scientists writing in Microbiology. The findings could lead to specialised probiotics that have a role in the prevention or treatment of conditions such as obesity.

Scientists from the Alimentary Pharmabiotic Centre (APC), Cork, University College Cork and Teagasc, in Ireland engineered a strain of Lactobacillus to produce a version of a molecule called conjugated linoleic acid (CLA). When this engineered bacterial strain was fed to mice, the researchers found that the composition of the mice's fat tissue was significantly altered, demonstrating that ingesting live bacteria can influence metabolism at remote sites in the body.

CLA is a fatty acid that is produced in different versions by different bacteria. One type, called t10, c12 CLA, has been shown to be associated with decreased body fat in humans and other animals. t10, c12 CLA also has the ability to inhibit the growth of colon cancer cells and induce their death. However, this type of CLA is only produced by certain types of bacteria including Propionibacterium acnes - a skin bacterium that can cause acne.

In this study, an enzyme-encoding gene from P. acnes was transferred to the Lactobacillus strain allowing it to produce t10, c12 CLA. Lactobacillus strains are common inhabitants of the normal gut flora and are often found in probiotic products. The researchers found that the level of t10, c12 CLA in the mice's fat tissue quadrupled when they were fed this recombinant probiotic. Thus, this study demonstrates that gut microbes have an impact on host metabolism, and in particular fat composition.

Dr Catherine Stanton, from Teagasc who led the study explained the significance of the results. "CLA has already been shown to alleviate non-alcoholic fatty liver disease that often accompanies obesity. Therefore, increasing levels of CLA in the liver by ingestion of a probiotic strain is of therapeutic relevance," she said. "Furthermore, fat is not an inert layer around our bodies, it is active and proinflammatory and is a risk factor for many diseases, including cancers. The work shows that there is potential to influence this through diet-microbe-host interactions in the gut."

The same group of researchers previously found that microbially produced CLA was able to reduce the viability of colon cancer cells by 92%. "It is possible that a CLA-producing probiotic may also be able to keep colon cancer cells in check. All our findings to date demonstrate that the metabolism of gut bacteria can modulate host cell activity in ways that are beneficial to the host," explained Dr Stanton. "We need to further investigate the effects of CLA-producing bacteria on human metabolism, but our work so far certainly opens up new possibilities for the use of probiotics for improvement of human health."
-end-


Microbiology Society

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.